5,541 results on '"Gertz, Morie A"'
Search Results
2. The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events
3. Switching from inotersen to eplontersen in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: analysis from NEURO-TTRansform
4. Real-life sensitivity of flow cytometry minimal residual disease assessment for plasma cell neoplasms
5. Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma
6. Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
7. Mode of progression in smoldering multiple myeloma: a study of 406 patients
8. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures
9. Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy: Multidisciplinary Collaborative Expert Opinion
10. Safety and efficacy of pegcetacoplan treatment for cold agglutinin disease and warm antibody autoimmune hemolytic anemia
11. Cumulative deficits frailty index and relationship status predict survival in multiple myeloma
12. Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma – updated results after 18-year follow-up
13. Retreatment of multiple myeloma with previously refractory drugs
14. Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies
15. Effect of Eplontersen on Cardiac Structure and Function in Patients With Hereditary Transthyretin Amyloidosis
16. Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group
17. Correction: Tracking daratumumab clearance using mass spectrometry: implications on M protein monitoring and reusing daratumumab
18. Correction: Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis
19. Correction: Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100
20. Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment
21. Is There Still a Role for Stem Cell Transplantation in Multiple Myeloma?
22. A proteomic atlas of kidney amyloidosis provides insights into disease pathogenesis
23. Muscle and fat composition in patients with newly diagnosed multiple myeloma
24. Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma
25. Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
26. Utility of flow cytometry screening before MRD testing in multiple myeloma
27. Defining drug/drug class refractoriness vs lines of therapy in relapsed/refractory multiple myeloma
28. Conditional survival in multiple myeloma and impact of prognostic factors over time
29. Amyloidosis
30. Hematological Associations in Amyloidosis
31. Prognostic impact of patient-reported symptoms in multiple myeloma
32. Prognostic impact of cytogenetic abnormalities detected by FISH in AL amyloidosis with daratumumab-based frontline therapy
33. Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy
34. Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas
35. Role of autologous haematopoietic cell transplantation in the treatment of systemic light chain amyloidosis in the era of anti-CD38 monoclonal antibodies
36. Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
37. Gastrointestinal amyloidosis: an often unexpected finding with systemic implications
38. Proteasome Inhibitor-Related Cardiotoxicity: Mechanisms, Diagnosis, and Management.
39. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen
40. Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment
41. Impact of the time interval between end of induction and autologous hematopoietic transplantation in newly diagnosed patients with multiple myeloma
42. Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapy
43. Long-term efficacy and safety of inotersen for hereditary transthyretin amyloidosis: NEURO-TTR open-label extension 3-year update
44. Outcomes after biochemical or clinical progression in patients with multiple myeloma
45. Phase 2 trial of ixazomib, cyclophosphamide, and dexamethasone for previously untreated light chain amyloidosis
46. How I approach smoldering multiple myeloma
47. Longitudinal Patient Reported Outcomes with CAR-T Cell Therapy Versus Autologous and Allogeneic Stem Cell Transplant
48. Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma
49. Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health‐Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin Amyloidosis.
50. Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.